Portal de Periódicos da CAPES

Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study

2015; Elsevier BV; Volume: 126; Issue: 12 Linguagem: Inglês

10.1182/blood-2015-04-639336

1528-0020

Yong Yang, Yuan Zhu, Jian-Zhong Cao, Yu‐Jing Zhang, Liming Xu, Zhiyong Yuan, Jun-Xin Wu, Wei Wang, Tao Wu, Bing Lü, Su-Yu Zhu, Li-Ting Qian, Fu-Quan Zhang, Xiao-Rong Hou, Ye‐Xiong Li,

Cutaneous lymphoproliferative disorders research

Key Points Patients with early-stage extranodal nasal-type NKTCL were classified as low risk or high risk using 5 independent prognostic factors. Risk-adapted therapy of RT alone for the low-risk group and RT consolidated by CT for the high-risk group proved the most effective treatment.